BARDA backs Medicines/Rempex antibiotic with $90m award
This article was originally published in Scrip
The Biomedical Advanced Research and Development Authority (BARDA) has awarded Rempex Pharmaceuticals, a wholly owned subsidiary of The Medicines Company (MDCO), a contract worth up to $90m to support the development of its investigational antibiotic Carbavance to treat antibiotic-resistant infections and act as an agent against two bioterrorism threats – melioidosis and glanders, two highly deadly infections.
You may also be interested in...
Repeat antibiotic entrepreneurs raised $33m to launch Qpex with assets from The Medicines Co. Also, Taiho increases VC fund to $300m and TP Therapeutics raises $80m.
The Medicines Co. is a few years behind its most recent beta-lactamase inhibitor competitors, but its antibiotic Carbavance is the only one with pivotal data that show superiority to a well-known drug in the same class for the treatment of hospital-based urinary tract infections.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.